Epigenetic silencing of glutaminase 2 in human liver and colon cancers

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Zhang, Jianbin ^a,b   Wang, Cheng ^c   Chen, Mingquan ^d   Cao, Jianping ^a   Zhong, Ying ^c   Chen, Liting ^c   Shen, Han Ming ^b   Xia, Dajing ^a,c  

^a ZHEJIANG UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Colon cancer; Gls2; Hepatocellular carcinoma; Methylation

Indexed keywords

ADULT; AGED; BASE SEQUENCE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; ENZYME REPRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUTAMINASE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84889991314     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-601     Document Type: Article

References (26)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010, 7(8):448-458. 10.1038/nrgastro.2010.100, 20628345.
2. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010, 118(6):818-824. 10.1289/ehp.0901388, 2898859, 20172840.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(6):1264-1273. e1261, 10.1053/j.gastro.2011.12.061, 3338949, 22537432.
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
5. Nishida N, Goel A. Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 2011, 12(2):130-137. 10.2174/138920211795564359, 3129047, 21966251.
6. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Gene 2012, 13(7):484-492.
7. Bergman Y, Cedar H. DNA methylation dynamics in health and disease. Nat Struct Mol Biol 2013, 20(3):274-281. 10.1038/nsmb.2518, 23463312.
8. Akhavan-Niaki H, Samadani AA. DNA methylation and cancer development: molecular mechanism. Cell Biochem Biophys 2013, 67(2):501-513. 10.1007/s12013-013-9555-2, 23508887.
9. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003, 163(4):1371-1378. 10.1016/S0002-9440(10)63495-5, 1868296, 14507645.
10. Herath NI, Leggett BA, MacDonald GA. Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroen Hepatol 2006, 21(1 Pt 1):15-21.
11. Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett 2014, 342(2):223-230. 10.1016/j.canlet.2012.01.038, 22306342.
12. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6(2):107-116. 10.1038/nrc1799, 16491070.
13. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 2010, 107(16):7455-7460. 10.1073/pnas.1001006107, 2867677, 20378837.
14. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010, 107(16):7461-7466. 10.1073/pnas.1002459107, 2867754, 20351271.
15. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005, 11(12):1306-1313. 10.1038/nm1320, 2637821, 16286925.
16. D'Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007, 8(10):813-824. 10.1038/nrm2256, 17848967.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
18. Jones PA, Baylin SB. The epigenetics of cancer. Cell 2007, 128:683-692. 10.1016/j.cell.2007.01.029, 17320506.
19. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012, 56(3):994-1003. 10.1002/hep.25706, 22407776.
20. Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q, Shu G. Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 2013, 44(5):795-801. 10.1016/j.humpath.2012.07.023, 23123137.
21. Riviere G, Lienhard D, Andrieu T, Vieau D, Frey BM, Frey FJ. Epigenetic regulation of somatic angiotensin-converting enzyme by DNA methylation and histone acetylation. Epigenetics: official journal of the DNA Methylation Society 2011, 6(4):478-489. 10.4161/epi.6.4.14961, 21364323.
22. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001, 20(15):1803-1815. 10.1038/sj.onc.1204252, 11313928.
23. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282(5393):1497-1501.
24. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997, 1(1):3-11. 10.1016/S1097-2765(00)80002-7, 9659898.
25. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992, 89(10):4495-4499. 10.1073/pnas.89.10.4495, 49109, 1584781.
26. Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH. p53 dependence of early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 1994, 9(6):1767-1773.